Fibrocell Science Inc. and Intrexon Corp. took their partnership to the next level with the submission of an investigational new drug (IND) application with the FDA for FCX-007, a gene-therapy drug candidate to treat the orphan condition recessive dystrophic epidermolysis bullosa, or RDEB.